| Source | Evidence on protein | Close homologs |
|---|---|---|
| Cuervo et al. | no | yes: 0 |
| Hassani et al. | no | yes: 0 |
| Forrest at al. (metacyclic) | no | yes: 0 |
| Forrest at al. (procyclic) | no | yes: 0 |
| Silverman et al. | no | yes: 0 |
| Pissara et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Pires et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Silverman et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Jamdhade et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 0, no: 7 |
| NetGPI | no | yes: 0, no: 7 |
Related structures:
AlphaFold database: A4H9I7
| Term | Name | Level | Count |
|---|---|---|---|
| GO:0003676 | nucleic acid binding | 3 | 6 |
| GO:0005488 | binding | 1 | 8 |
| GO:0008270 | zinc ion binding | 6 | 6 |
| GO:0043167 | ion binding | 2 | 8 |
| GO:0043169 | cation binding | 3 | 8 |
| GO:0046872 | metal ion binding | 4 | 8 |
| GO:0046914 | transition metal ion binding | 5 | 6 |
| GO:0097159 | organic cyclic compound binding | 2 | 6 |
| GO:1901363 | heterocyclic compound binding | 2 | 6 |
| Leishmania | From | To | Domain/Motif | Score |
|---|---|---|---|---|
| CLV_NRD_NRD_1 | 54 | 56 | PF00675 | 0.365 |
| CLV_NRD_NRD_1 | 87 | 89 | PF00675 | 0.417 |
| CLV_PCSK_KEX2_1 | 59 | 61 | PF00082 | 0.594 |
| CLV_PCSK_KEX2_1 | 87 | 89 | PF00082 | 0.426 |
| CLV_PCSK_PC1ET2_1 | 59 | 61 | PF00082 | 0.549 |
| CLV_PCSK_PC7_1 | 55 | 61 | PF00082 | 0.207 |
| DEG_SPOP_SBC_1 | 7 | 11 | PF00917 | 0.510 |
| DOC_MAPK_gen_1 | 87 | 95 | PF00069 | 0.425 |
| DOC_MAPK_MEF2A_6 | 87 | 95 | PF00069 | 0.345 |
| DOC_MAPK_RevD_3 | 75 | 89 | PF00069 | 0.478 |
| DOC_USP7_MATH_1 | 17 | 21 | PF00917 | 0.660 |
| DOC_USP7_MATH_1 | 36 | 40 | PF00917 | 0.433 |
| DOC_USP7_MATH_1 | 5 | 9 | PF00917 | 0.561 |
| DOC_USP7_UBL2_3 | 52 | 56 | PF12436 | 0.435 |
| DOC_USP7_UBL2_3 | 68 | 72 | PF12436 | 0.397 |
| DOC_WW_Pin1_4 | 75 | 80 | PF00397 | 0.608 |
| LIG_14-3-3_CanoR_1 | 30 | 34 | PF00244 | 0.553 |
| LIG_Actin_WH2_2 | 89 | 104 | PF00022 | 0.504 |
| LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.507 |
| LIG_BRCT_BRCA1_1 | 38 | 42 | PF00533 | 0.438 |
| LIG_FHA_2 | 76 | 82 | PF00498 | 0.430 |
| LIG_LIR_Gen_1 | 31 | 42 | PF02991 | 0.219 |
| LIG_LIR_Gen_1 | 80 | 91 | PF02991 | 0.606 |
| LIG_LIR_Nem_3 | 31 | 37 | PF02991 | 0.343 |
| LIG_LIR_Nem_3 | 80 | 86 | PF02991 | 0.607 |
| LIG_NRP_CendR_1 | 107 | 110 | PF00754 | 0.466 |
| LIG_SH2_CRK | 34 | 38 | PF00017 | 0.506 |
| LIG_SH2_STAP1 | 46 | 50 | PF00017 | 0.405 |
| LIG_SH2_STAT5 | 34 | 37 | PF00017 | 0.463 |
| MOD_CK1_1 | 20 | 26 | PF00069 | 0.556 |
| MOD_CK1_1 | 8 | 14 | PF00069 | 0.483 |
| MOD_GlcNHglycan | 10 | 13 | PF01048 | 0.573 |
| MOD_GlcNHglycan | 18 | 22 | PF01048 | 0.685 |
| MOD_GlcNHglycan | 3 | 6 | PF01048 | 0.500 |
| MOD_GlcNHglycan | 60 | 63 | PF01048 | 0.508 |
| MOD_GSK3_1 | 1 | 8 | PF00069 | 0.563 |
| MOD_GSK3_1 | 101 | 108 | PF00069 | 0.564 |
| MOD_GSK3_1 | 17 | 24 | PF00069 | 0.569 |
| MOD_GSK3_1 | 36 | 43 | PF00069 | 0.508 |
| MOD_NEK2_1 | 1 | 6 | PF00069 | 0.561 |
| MOD_NEK2_1 | 42 | 47 | PF00069 | 0.544 |
| MOD_NEK2_2 | 21 | 26 | PF00069 | 0.476 |
| MOD_PKA_1 | 58 | 64 | PF00069 | 0.476 |
| MOD_PKA_2 | 29 | 35 | PF00069 | 0.463 |
| MOD_Plk_1 | 17 | 23 | PF00069 | 0.468 |
| MOD_Plk_1 | 28 | 34 | PF00069 | 0.355 |
| MOD_Plk_4 | 29 | 35 | PF00069 | 0.536 |
| MOD_ProDKin_1 | 75 | 81 | PF00069 | 0.602 |
| MOD_SUMO_rev_2 | 99 | 108 | PF00179 | 0.671 |
| TRG_ENDOCYTIC_2 | 34 | 37 | PF00928 | 0.506 |
| TRG_ER_diArg_1 | 86 | 88 | PF00400 | 0.416 |
| TRG_NLS_MonoExtC_3 | 54 | 59 | PF00514 | 0.508 |
| TRG_NLS_MonoExtN_4 | 52 | 59 | PF00514 | 0.512 |
| Protein | Taxonomy | Sequence identity | Coverage |
|---|---|---|---|
| A0A1X0P725 | Trypanosomatidae | 55% | 100% |
| A0A3Q8I9Z0 | Leishmania donovani | 84% | 100% |
| A4HXV0 | Leishmania infantum | 85% | 100% |
| E9ARL3 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 82% | 100% |
| Q4QDW6 | Leishmania major | 76% | 100% |
| V5BM68 | Trypanosoma cruzi | 55% | 100% |